Physicochemical compatibility and stability of urapidil-propofol admixtures during simulated Y-site Administration
Background/Objectives: Urapidil with propofol is clinically efficient against elevated blood pressure during sedation. However, their physicochemical compatibility and emulsion stability upon continuous infusion remain unclear. This study aimed to evaluate different mixing ratios and diluents, thereby proving the safety limits for their co-administration. Methods: Urapidil solutions prepared with…
Background and objectives of this study involved assessing the compatibility and stability of urapidil-propofol mixtures during simulated Y-site administration. Researchers sought to determine safe mixing ratios and diluents for co-administration.
Urapidil solutions were prepared using either sodium chloride (NS) or glucose injection (GS) and then emulsified with propofol in varying ratios (by volume). These mixtures were stored for 12 hours.
Physical compatibility was evaluated through visual inspection, pH, osmolality, mean droplet diameter (MDD), polydispersity index (PDI), and zeta potential measurements. Percentage of fat globules larger than 5 micrometers (PFAT5) was also assessed.
Chemical stability was determined using high-performance liquid chromatography. Results showed that both urapidil hydrochloride and propofol remained pure at 95% concentration. MDD averaged 0.05% after 2-8 hours.
However, when GS was used as the diluent at a 1:2 ratio, PFAT5 remained elevated compared to the other conditions evaluated.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
